Literature DB >> 7018165

Effectivity and acceptability of oral contraceptives containing natural and artificial estrogens in combination with a gestagen. A controlled double-blind investigation.

J Serup, E Bostofte, S Larsen, J Westergaard.   

Abstract

With the purpose of investigating effectivity and acceptability of an oral contraceptive containing micronized natural estrogens (estradiol-17 beta 4 mg + estriol 2 mg/norethisterone acetate 3 mg per tablet) versus a contraceptive containing artificial estrogen (ethinyl estradiol 50 micrograms/ norethisterone acetate 3 mg per tablet), a controlled double-blind investigation was performed in 111 young women. The investigation was designed for 12 cycles. The tablets were given consecutively for 3 weeks with 1 week's interruption. In the natural estrogen group 57 women completed 504 cycles, in the artificial estrogen group 54 women completed 510 cycles (Table 1). No pregnancies occurred. There were highly significantly more terminations due to bleeding irregularities (p less than 0.001), and highly significantly more spotting (p less than 0.001), breakthrough (p less than 0.001) and amenorrhea (p less than 0.001) episodes in the natural estrogen group (Tables II and III). Bleeding irregularities on natural estrogens did not subside during the trial (Table IV). There were a few more psychiatric and CNS symptoms on natural estrogen (p less than 0.05), but other side effects did not differ between the two preparations (Table V). Blood pressure and weight did not vary significantly. Despite documented metabolic advantages, the natural estrogen tablet investigated was not found to be clinically acceptable for general usage because of the high incidence of bleeding irregularities. It is conceivable that a change of the estrogen/gestagen ratio, using a variable 3-week schedule, would reduce the number of bleeding irregularities.

Entities:  

Keywords:  Abdominal Cramps; Acne; Amenorrhea; Appetite Alterations; Blood Pressure; Contraception; Contraceptive Agents; Contraceptive Agents, Estrogen; Contraceptive Agents, Female; Contraceptive Methods; Contraceptive Methods--side effects; Control Groups; Decreased Libido; Depression; Dizziness; Double-blind Studies; Dropouts; Dysmenorrhea; Edema; Family Planning; Fatigue; Headache; Infections; Mammary Gland Effects; Metrorrhagia; Nausea; Nervousness; Oral Contraceptives, Combined; Oral Contraceptives--side effects; Research Methodology; Studies; Vomiting

Mesh:

Substances:

Year:  1981        PMID: 7018165

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  3 in total

1.  Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in comparison to one containing levonorgestrel and ethinylestradiol on markers of endocrine function.

Authors:  Ulla M Ågren; Marjatta Anttila; Kristiina Mäenpää-Liukko; Maija-Liisa Rantala; Hilkka Rautiainen; Werner F Sommer; Ellen Mommers
Journal:  Eur J Contracept Reprod Health Care       Date:  2011-09-26       Impact factor: 1.848

Review 2.  An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest.

Authors:  Franca Fruzzetti; Florence Trémollieres; Johannes Bitzer
Journal:  Gynecol Endocrinol       Date:  2012-04-02       Impact factor: 2.260

3.  Contraceptive efficacy and safety of estradiol valerate/dienogest in a healthy female population: a multicenter, open-label, uncontrolled Phase III study.

Authors:  Qi Yu; Zirong Huang; Mulan Ren; Qing Chang; Zhongqi Zhang; Susanne Parke
Journal:  Int J Womens Health       Date:  2018-06-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.